Kexiao Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kexiao Guo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amy E. Stewart
Department of Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC
54 shared publications - Chun-Hsiang Lai
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina
54 shared publications - David G. Kirsch
Department of Radiation Oncology, Duke University , Durham, NC
54 shared publications - Jianmin Fu
Pharmaron, Beijing, P.R. China
54 shared publications - Katherine Deland
Department of Radiation Oncology, and
54 shared publications - Kathleen A. Ashcraft
Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina
54 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
MDA-MB-231 clonogenic survival treated with XRD-0394
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
MDA-MB-231 clonogenic survival treated with XRD-0394
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
FaDu clonogenic survival treated with XRD-0394
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
FaDu clonogenic survival treated with XRD-0394
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
In vivo efficacy with radiation
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
In vivo efficacy with radiation
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
Clonogenic survival treated with ATMi, DNA-PKi, the combination and XRD-0394
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
Clonogenic survival treated with ATMi, DNA-PKi, the combination and XRD-0394
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Kinase Panel 2 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
Results of Kinase Panel Screen-2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKinase Panel 2 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors
Results of Kinase Panel Screen-2